Category: Patently BIOtech
BIO on CNBC: IPR System Weakens Medical Innovation
Last night Ron Cohen, M.D., CEO of Acorda Therapeutics and BIO’s board chair, appeared on …
Here are the Facts about the IPR Kill Rate
FiercePhrma recently ran an article repeating a dubious analysis of the crisis caused by the …
102 Organizations Urge Congress to Maintain a Strong Patent System and Protect Innovation
A diverse group of more than 100 national and state-based advocacy organizations have united to …
Register for the 2015 BIO IP & Diagnostics Symposium!
The Third Annual BIO IP & Diagnostics Symposium takes place on September 18, 2015 in Alexandria, …
New Report Suggests RDP Does Not Increase Healthcare Expenditures
A new paper by the Geneva Network suggests that increasing the period of regulatory data …
225th Anniversary of First U.S. Patent
225 years ago last Friday the first U.S. patent was issued to Samuel Hopkins for …
Seventy Nine House Members Express Concern with H.R. 9
House leaders made the decision earlier this month to remove patent reform legislation from the …
CNBC Commentary: Hedge funds, 'reverse trolls' crushing biopharma innovation
Patents are the lifeblood of medical innovation. They are the cornerstone that enables companies to …
Understanding the Wider Implications of HR 9: Patent Reform's Impact on Agriculture
The House Judiciary Committee recently approved H.R. 9, the Innovation Act, legislation they hoped would …
IP Sessions at BIO 2015: The Evolving Landscape of Patentable Subject Matter
The IP Track at BIO 2015 had a number of incredible educational sessions concerning the …